SecBot SecBot
Insider Cluster (3 insiders) ·Filed Nov 12, 2026

CYTK

CYTOKINETICS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 14h ago
Insider cluster: 3 insiders, $0.8M total
Actionable Insight • Neutral

All sales were pre-planned under 10b5-1 plans, so the cluster does not signal a change in insider sentiment. Monitor the upcoming supplemental NDA filing for aficamten and any subsequent insider activity for directional cues.

DirectionNeutral
Confidencehigh
Horizonweeks

MYQORZO

▲ Bullish Named in this insider cluster
Impact
Phase
Approved
Time to market
Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
Next catalyst
None dated

What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$56.13
T+0 close · Nov 12, 2026 · via day close
Latest settled
−5.27%
T+1 · $53.17
Vs SPY
−3.36%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $56.13entry
  2. T+1 · 16h ago −5.27%α −3.36% · $53.17
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three Cytokinetics insiders, including the CEO and EVP of R&D, sold a total of $824K in open-market sales over a week, all under 10b5-1 plans. The sales follow a strong Q3 2026 earnings beat and reaffirmed guidance, but the CEO's $471K sale is material relative to the $8.2B market cap (0.006%). The cluster is neutral given the small size relative to market cap and the pre-planned nature of the trades.

Key Financial Metrics

Direction
selling
Total Value
$824.0K
Insiders
3

Key Facts

  • CEO Blum sold 7,500 shares for $471K on 2026-11-02 under a 10b5-1 plan
  • EVP Malik sold 3,500 shares for $220K on 2026-11-03 under a 10b5-1 plan
  • Director Parshall sold 5,000 shares total ($273K) on 2026-11-09 under a 10b5-1 plan
  • Total open-market sales: $824K, or 0.01% of $8.2B market cap
  • All sales were pre-planned under 10b5-1 trading plans
  • Q3 2026 earnings beat consensus on revenue ($47.6M vs $42.3M) and EPS (-$1.37 vs -$1.41 consensus)
  • Company reaffirmed 2026 guidance and plans to file supplemental NDA for aficamten in Q4 2026

Financial Impact

Total insider sales of $824K represent 0.01% of market cap, well below the 0.1% materiality threshold

dilution

Risk Factors

  • Insider sales are small relative to market cap and pre-planned, limiting their informational value
  • No unplanned insider buying to offset the sales

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CYTK-1794519742056

Track record

46 reports on CYTK

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Viewing Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (10h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026